Cancer Blood Tests Can Jumpstart Diagnoses and Targeted Therapy
Blood tests for circulating tumor DNA could be used to detect cancer 18 months prior to clinical diagnosis by CT scan.
Complete the form below to unlock access to ALL audio articles.
New research led by a UC Davis Comprehensive Cancer Center clinical scientist shows blood tests used to hunt for cancer DNA may help detect cancers faster and guide the use of targeted therapies. The results of the study were published in NPJ Precision Oncology, an international, peer-reviewed journal focused on targeted cancer care based on a person’s genetics.
UC Davis Professor of Medicine and the cancer center’s Chief Translational Officer Nicholas Mitsiades and his research team from several U.S. cancer centers made a potentially life-saving discovery. While monitoring a patient for prostate cancer DNA after treatment, the researchers identified genetic material coming, not from prostate cancer, but from a type of cancer that starts in or near the urinary bladder. Their analysis showed that DNA from the cancer could be detected in the blood at least 18 months prior to clinical diagnosis using conventional screening such as computed tomography (CT).
When Mitsiades’ team discovered the asymptomatic urothelial cancer, they were able to use data from the blood sample to develop a targeted treatment plan based on the newly detected cancer’s specific gene mutations.
DNA sequencing in blood provides a fast, less invasive method for cancer detection
DNA from some cancers may circulate in a patient’s blood and can be extracted from a simple blood sample. Scientists can genetically sequence the DNA—determining the order of the building blocks of genetic instructions—and characterize the cancer based on what’s found in the blood sample.
“We want to collect information about a patient’s cancer in the least invasive way possible,” Mitsiades said. “The more we can learn about a patient’s cancer, the more we can treat it with safer and hopefully more effective drugs by targeting mutations that show up in the DNA sequencing.”
Sequencing of tumor DNA circulating in the blood is a remarkable technological advancement. While a tissue biopsy is needed for a tumor’s initial diagnosis, it is painful and inconvenient to repeatedly collect samples of tumor tissue. By sequencing tumor DNA from blood samples, a patient’s tumor can be monitored with little discomfort. It can also reveal mutations that suggest a particular treatment path. “Driver mutations” that spur the growth of cancer can be found in blood samples and indicate an aggressive cancer long before it can be detected on other types of tests.
Using circulating tumor DNA analysis to enhance patient treatment
“It appears that by sequencing DNA circulating in the blood, we can see evidence of cancer growth months or years before it shows up in CT scans,” Mitsiades said. “What we need now are clinical trials that will examine whether, by acting upon DNA information from a patient’s blood, we can help them live longer.”
For years, the gold standard of care for cancer treatment was to treat patients once tumors showed visible signs of growth on scans.
Now, with the development of precision oncology tools, like circulating tumor DNA sequencing, Mitsiades and his colleagues think there are opportunities to respond to cancer earlier, identify cancers that have acquired mutations driving resistance to current therapy, and quickly pivot towards alternative, targeted therapies that may be less toxic than chemotherapy.
“These new technologies are opening exciting opportunities to intervene earlier for the benefit of our patients,” Mitsiades said.
He said that DNA sequencing is becoming more widely covered by insurers and incorporated into the standard of care. At UC Davis Comprehensive Cancer Center, genetic tests are already offered regularly to patients who also have the option to participate in precision oncology research at the cancer center.
“In October, Gov. Gavin Newsom signed into law legislation that requires Medi-Cal and private insurers to cover medically necessary biomarker testing,” Mitsiades said. “This will allow more people to access individualized cancer treatments based on the genetic makeup of their cancer.”
Reference: Huang Q, Mitsiades I, Dowst H, et al. Incidental detection of FGFR3 fusion via liquid biopsy leading to earlier diagnosis of urothelial carcinoma. npj Precis Onc. 2023;7(1):1-8. doi: 10.1038/s41698-023-00467-9
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.